Generic Medicine Info
Should be taken with food.
Hypersensitivity to aspirin, salicylates and other NSAIDs; history of asthma attacks, angioedema, urticaria, or rhinitis precipitated by aspirin or other NSAIDs. Nasal polyps associated with asthma; active or history of recurrent peptic ulceration and gastrointestinal haemorrhage; haemorrhagic diathesis, coagulation disorders (e.g. haemophilia, thrombocytopenia), severe cardiac failure, gout. Severe renal and hepatic impairment. Children <16 years and/or those who have or are recovering from chickenpox or flu-like symptoms. Pregnancy (doses >100 mg daily during 3rd trimester) and lactation (during long-term use and/or high doses). Concomitant use with methotrexate ≥15 mg weekly.
Special Precautions
Patient with allergic disease, asthma, chronic respiratory disease, anaemia, less severe cardiac failure, SLE, connective tissue disorders, thyrotoxicosis, hypertension, G6PD deficiency, risk factors for peptic ulcer disease (e.g. alcoholism, smoking). Patients undergoing surgical procedures, including tooth extraction. Not recommended for use during menorrhagia. Avoid use for 6 weeks following varicella vaccination. May mask signs and symptoms of infection. Concomitant use with anticoagulants (e.g. warfarin), thrombolytic, other antiplatelet agents, SSRIs, and oral corticosteroids. Avoid concomitant use with other NSAIDs. Dehydrated and debilitated patients. Mild to moderate renal and hepatic impairment. Elderly. Pregnancy (1st-2nd trimester). Monitoring Parameters Obtain CBC, Fe studies, ferritin, stools for occult blood, and liver and renal function tests during prolonged therapy. Monitor for signs and symptoms of hypersensitivity reactions and bleeding.
Adverse Reactions
Significant: Bronchospasm, asthma attacks, hypersensitivity reactions, prolonged bleeding time; reduced uric acid excretion (low dose use); haemolytic anaemia (in patients with G6PD deficiency), medication overuse headache (long-term use), salicylism (repeated use of large doses). Blood and lymphatic system disorders: Rarely, thrombocytopenia, agranulocytosis, aplastic anaemia. Ear and labyrinth disorders: Reduced hearing ability, tinnitus, vertigo. Gastrointestinal disorders: Dyspepsia, nausea, vomiting, diarrhoea, mild stomach pain, heartburn. Hepatobiliary disorders: Hepatic insufficiency, hepatitis. Investigations: Increased transaminases. Nervous system disorders: Headache. Renal and urinary disorders: Impaired renal function, Na and fluid retention, urate kidney stones, haematuria. Reproductive system and breast disorders: Rarely, menorrhagia. Respiratory, thoracic and mediastinal disorders: Rhinitis, dyspnoea. Skin and subcutaneous tissue disorders: Urticaria.
Potentially Fatal: Gastrointestinal bleeding, ulceration, and perforation. Rarely, Reye's syndrome, serious skin reactions (e.g. Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis).
C D if full-dose used in 3rd trimester.
Drug Interactions
Increased risk of bleeding with other antiplatelet agents (e.g. clopidogrel, dipyridamole), anticoagulants (e.g. heparin, warfarin), and thrombolytics. Increased risk of gastrointestinal bleeding or ulceration with other NSAIDs, SSRIs (e.g. sertraline, paroxetine), and corticosteroids. Reverses the effect of uricosuric agents (e.g. probenecid, sulfinpyrazone). May increase the effects of antidiabetics (e.g. sulfonylureas, insulins) and thiopental. Impairs the renal excretion of lithium and digoxin, thus increasing the plasma concentrations of the drugs. Increased excretion with antacids. May decrease the effects of diuretics (e.g. spironolactone, furosemide) and antihypertensive agents (e.g. ACE inhibitors, β-blockers). May result in severe acidosis and increased CNS toxicity with carbonic anhydrase inhibitors (e.g. acetazolamide). May increase the nephrotoxic effect of ciclosporin and tacrolimus. Increases the plasma concentration of zafirlukast. Reduces the binding of phenytoin and valproic acid to serum albumin, resulting in increased free concentration of the drugs. Concomitant use with metamizole or ibuprofen may reduce the cardioprotective effect of aspirin. May enhance the adverse or toxic effect of varicella virus-containing vaccines (particularly the risk for Reye's syndrome), sulfonamides, and vancomycin (particularly ototoxicity). Increased rate of absorption with metoclopramide and domperidone.
CIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) / Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disclaimer: This information is independently developed by CIMS based on aspirin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in